Erythroleukaemia following treatment of Hodgkin's disease.
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000139:chemically induced*; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D011239:Prednisolone / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D014747:Vinblastine / Q000009:adverse effects
D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014747:Vinblastine; D011239:Prednisolone